Literature DB >> 11145239

Characterization and in vitro methotrexate release from methotrexate/gelatin conjugates of opposite conjugate bond polarity.

B J Bowman1, C M Ofner.   

Abstract

PURPOSE: Our laboratory has previously prepared gelatin/ methotrexate (MTX) conjugates containing mixed conjugation sites and by-product crosslinking, both of which may alter conjugate effectiveness. In this study, we prepared and evaluated gelatin/MTX conjugates having specific conjugate bond sites and minimal by-product crosslinking.
METHODS: Opposite polarity conjugates were produced by coupling gelatin having blocked amino groups with MTX (G-MTX) and by coupling MTX having blocked amino groups with gelatin (M-GEL) using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide HCl. Amino groups were blocked using citraconic anhydride and deblocked under acidic conditions. Gelatin and MTX contents were determined spectrophotometrically. The stability of each conjugate was determined by evaluating their in vitro release of MTX in isotonic buffer at pH 7.4 and 37 degrees C for 7 days.
RESULTS: The G-MTX and M-GEL conjugates contained 21 and 1.2 mole MTX/mole gelatin and released 12 and 17% MTX by 7 days resulting in pseudo-first order release rate constants of 0.76x10(-3) and 1.0x10(-3) hr(-1), respectively. Alternate MTX species (< or =10%) were detected during the release study and were attributed to low molecular weight gelatin/MTX fragments and MTX polymers.
CONCLUSIONS: Gelatin/MTX conjugates having opposite conjugate bond polarities and minimal by-product crosslinking have been produced and slowly released MTX by hydrolytic cleavage indicating good stability for future cell culture studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11145239     DOI: 10.1023/a:1026460023503

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  21 in total

1.  The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats.

Authors:  G Stehle; H Sinn; A Wunder; H H Schrenk; S Schütt; W Maier-Borst; D L Heene
Journal:  Anticancer Drugs       Date:  1997-08       Impact factor: 2.248

Review 2.  Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs.

Authors:  Y Takakura; M Hashida
Journal:  Crit Rev Oncol Hematol       Date:  1995-03       Impact factor: 6.312

3.  Preparation and characterization of methotrexate-immunoglobulin conjugates.

Authors:  M K Ghosh; D O Kildsig; A K Mitra
Journal:  Drug Des Deliv       Date:  1989-01

4.  Synthesis of site-specific methotrexate-IgG conjugates. Comparison of stability and antitumor activity with active-ester-based conjugates.

Authors:  J Kralovec; M Singh; M Mammen; A H Blair; T Ghose
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Rapid quantitation of methotrexate and its metabolites in human serum, urine and bile, using solid-phase extraction and high-performance liquid chromatography.

Authors:  B Nuernberg; M Kohlbrenner; R Faulkner; D E Furst
Journal:  J Chromatogr       Date:  1989-02-24

6.  Ready separation of proteins from nucleoprotein complexes by reversible modification of lysine residues.

Authors:  J K Shetty; J E Kinsella
Journal:  Biochem J       Date:  1980-10-01       Impact factor: 3.857

7.  Characterization and in vitro release of methotrexate from gelatin/methotrexate conjugates formed using different preparation variables.

Authors:  A Kosasih; B J Bowman; R J Wigent; C M Ofner
Journal:  Int J Pharm       Date:  2000-08-25       Impact factor: 5.875

8.  Studies on the mechanism of action of an MTX-HSA-MoAb conjugate.

Authors:  J J Fitzpatrick; M C Garnett
Journal:  Anticancer Drug Des       Date:  1995-01

9.  The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. V. Alternative method for preparation of serum albumin-methotrexate derivative.

Authors:  L Bures; A Lichý; J Bostík; M Spundová
Journal:  Neoplasma       Date:  1990       Impact factor: 2.575

10.  Potentiation of in vivo antitumor effects of recombinant interleukin-1 alpha by gelatin conjugation.

Authors:  Y Tabata; K Uno; Y Ikada; T Kishida; S Muramatsu
Journal:  Jpn J Cancer Res       Date:  1993-06
View more
  3 in total

1.  Carbodiimide induced cross-linking, ligand addition, and degradation in gelatin.

Authors:  Christopher R Cammarata; Mitchell E Hughes; Clyde M Ofner
Journal:  Mol Pharm       Date:  2015-02-06       Impact factor: 4.939

2.  Preparation, drug release, and cell growth inhibition of a gelatin: doxorubicin conjugate.

Authors:  Darren C Wu; Christopher R Cammarata; Hyun Joo Park; Brian T Rhodes; Clyde M Ofner
Journal:  Pharm Res       Date:  2013-05-18       Impact factor: 4.200

3.  The effect of molecular weight, drug load, and charge of gelatin-MTX conjugates on growth inhibition of HL-60 leukemia cells.

Authors:  Chao-Sheng Chen; Clyde M Ofner
Journal:  Pharm Res       Date:  2008-10-31       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.